Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana’s latest 10-K stretches well past 300 pages—packed with medical-loss ratios, Medicare Advantage Star Ratings, and CMS audit risk disclosures that can overwhelm even seasoned analysts. If you have ever tried to pinpoint how pharmacy benefit margins or risk-adjustment revenue affect earnings, you know the challenge.
Stock Titan removes that friction. Our AI reads every Humana annual report 10-K simplified, Humana quarterly earnings report 10-Q filing, and Humana 8-K material events explained the moment they post to EDGAR. You’ll see plain-English highlights of segment profitability, regulatory updates, and capital-return plans—plus instant alerts for Humana Form 4 insider transactions real-time.
- Track Humana insider trading Form 4 transactions to monitor executive sentiment.
- Compare medical-cost trends quarter over quarter with AI-tagged tables pulled directly from each filing.
- Review Humana proxy statement executive compensation to understand incentive alignment with Medicare growth.
Need deeper context? Use our “Explain� toggle for understanding Humana SEC documents with AI; it connects statutory language to real-world impact. Our coverage spans every form—from shelf registrations to the smallest 11-K—so you never miss a disclosure. Whether you’re running a DCF model, scanning an Humana earnings report filing analysis, or verifying Humana executive stock transactions Form 4, Stock Titan delivers the insights professionals rely on—without the regulatory maze.
Humana Inc. (HUM) Form 4 � insider equity change filed 08-05-2025. SVP & Chief Accounting Officer John-Paul W. Felter converted 211 restricted stock units under the 2019 Stock Incentive Plan on 08-01-2025 (Code M). Immediately upon vesting, 97 shares were sold (Code F) at $248.415 to cover tax obligations, a routine withholding transaction yielding no cash proceeds to the insider. Net of withholding, Felter’s direct common-stock holding rose by 114 shares to 1,881 shares. Derivative holdings fell to 115 RSUs after the conversion, and 1,203 additional RSUs remain reported in footnote (4). No open-market purchases or sales were disclosed. The activity represents scheduled vesting rather than discretionary trading, and the dollar value (<~$26k of tax-withheld shares) is immaterial relative to HUM’s market capitalization, suggesting limited signaling value for investors.
Humana Inc. (NYSE: HUM) filed its Q2-25 Form 10-Q. Premium and service revenues rose 10% YoY to $32.4 bn for the quarter and 9% YoY to $64.5 bn for the first half. Growth was driven by Medicare Advantage membership and higher services revenue.
Quarterly results weakened: operating income fell 4% to $1.1 bn, while net income dropped 20% to $545 m ($4.51 diluted EPS vs. $5.62). Benefit expense grew 10% and other expense jumped to $200 m, reflecting value-creation and impairment charges. The medical benefit ratio ticked up 90 bp to 89.8%.
Year-to-date performance stronger: YTD net income climbed 26% to $1.79 bn with diluted EPS of $14.81 (+26%), aided by lower benefit ratio (88.4%) and higher operating margins.
Balance sheet: cash & equivalents doubled to $4.0 bn; total assets $50.4 bn. Long-term debt rose to $12.6 bn after issuing $1.5 bn of new senior notes (5.55% 2035; 6.00% 2055) and retiring $600 m notes due 2025. A new $5 bn 5-year revolving credit facility replaced prior lines; no outstanding borrowings.
Capital return: $100 m share buybacks (0.4 m shares at $234 avg) and $0.885 quarterly dividend ($321 m YTD). Remaining authorization: $2.8 bn.
Key risks & items: Medicare Part D redesign effective 2025, ongoing cost-saving initiatives (additional charges expected), $32 m intangible impairment, and put/call obligations on WCAS clinic JV valued at $1.25 bn. Effective tax rate 24.6%. Shares outstanding 120.3 m.
FAQ
What is the current stock price of Humana (HUM)?
What is the market cap of Humana (HUM)?
